| (E)-FeCP-oxindole |
|
|
|
|
| (Rac)-SAR131675 |
|
|
|
|
| (rac)-ZK-304709 |
|
|
|
|
| (S)-SAR131675 |
|
|
|
99.72% |
| (Z)-FeCP-oxindole |
|
|
|
99.62% |
| (Z)-Guggulsterone |
|
|
|
99.41% |
| (Z)-Orantinib |
|
|
|
99.44% |
| (Z)-SU14813 |
|
|
|
|
| (±)-Aiphanol |
|
|
|
|
| (±)-Glaziovine |
|
|
|
|
| 1,3,5-Tricaffeoylquinic acid |
|
|
|
|
| MET kinase-IN-4 |
|
|
|
99.00% |
| 19-epi-Scholaricine |
|
|
|
99.14% |
| 10Z-Hymenialdisine |
|
|
|
|
| 3-Methylthienyl-carbonyl-JNJ-7706621 |
|
|
|
|
| 4-Methoxycinnamic acid ethyl ester |
|
|
|
98.72% |
| 4-TCPA |
|
|
|
|
| 4SC-203 |
|
|
|
98.98% |
| 5-O-Methylvisammioside |
|
|
|
99.90% |
| 5Z-7-Oxozeaenol |
|
|
|
99.30% |
| 5α-Hydroxycostic acid |
|
|
|
95.17% |
| 6'-Sialyllactose |
|
|
|
99.60% |
| 6'-Sialyllactose sodium |
|
|
|
98.05% |
| 7-Hydroxyneolamellarin A |
|
|
|
|
| A-176120 |
|
|
|
|
| AAL993 |
|
|
|
99.14% |
| AC-P19M |
|
|
|
|
| Acrizanib |
|
|
|
99.84% |
| AFG210 |
|
|
|
|
| Aflibercept (VEGF Trap) |
|
|
|
97.66% |
| AG-13958 |
|
|
|
99.69% |
| AG-13958 (mono(hydrochloride)) |
|
|
|
|
| AG-28262 |
|
|
|
|
| AG01 |
|
|
|
95.10% |
| AGN-745 |
|
|
|
|
| AGN-745 sodium |
|
|
|
|
| AGN-745 sodium scrambled negative control |
|
|
|
|
| AGW-11 |
|
|
|
|
| AhR modulator-1 |
|
|
|
|
| AK-778-XXMU |
|
|
|
99.96% |
| ALN-3133 sodium |
|
|
|
|
| ALN-3133 sodium scrambled negative control |
|
|
|
|
| Altiratinib |
|
|
|
99.29% |
| AM9928 |
|
|
|
|
| AMG-47a |
|
|
|
99.19% |
| AMG-Tie2-1 |
|
|
|
99.5% |
| Angiogenesis inhibitor 6 |
|
|
|
|
| Anomalin A |
|
|
|
|
| Ansornitinib |
|
|
|
98.23% |
| Anti-DCBLD2/ESDN Antibody (FA19-1) |
|
|
|
|
| Anti-Human/Rat VEGF Antibody (A.4.6.1) |
|
|
|
|
| Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) |
|
|
|
|
| Anti-Mouse VEGF Antibody (G6-31) |
|
|
|
|
| Anti-Mouse VEGF-A Antibody (2G11-2A05) |
|
|
|
97.40% |
| Anti-Mouse VEGFR-2 Antibody (DC101) |
|
|
|
99% |
| Anti-Mouse VEGFR-2 Antibody (DC101-Mouse IgG2a) |
|
|
|
|
| Anti-VEGFB Antibody (CSL346) |
|
|
|
≥99.0% |
| Anti-VEGFR1/FLT1 Antibody |
|
|
|
|
| Anti-VEGFR2/KDR/CD309 Antibody |
|
|
|
|
| Anti-VEGFR2/KDR/CD309 Antibody (AT001) |
|
|
|
|
| Antiangiogenic agent 9 |
|
|
|
|
| Anticancer agent 276 |
|
|
|
|
| Antiproliferative agent-20 |
|
|
|
|
| Antiproliferative agent-54 |
|
|
|
|
| Antiproliferative agent-57 |
|
|
|
|
| Apatinib-d8 free base |
|
|
|
92.03% |
| Apolipoprotein KV domain (67-77) |
|
|
|
|
| Apoptotic agent-4 |
|
|
|
|
| APX004 |
|
|
|
|
| Arginyl-Glutamine |
|
|
|
|
| Arginyl-Glutamine TFA |
|
|
|
|
| ASKG-712 |
|
|
|
|
| AST 487 |
|
|
|
98.90% |
| AT-533 |
|
|
|
98.38% |
| ATWLPPR Peptide |
|
|
|
99.63% |
| Auriculasin |
|
|
|
98.54% |
| AXL/Angiokinase-IN-1 |
|
|
|
|
| Azaspirene |
|
|
|
|
| AZD2932 |
|
|
|
98.16% |
| B-Raf IN 17 |
|
|
|
|
| BAT5906 |
|
|
|
|
| Bevacizumab vedotin |
|
|
|
97.72% |
| Bevasiranib |
|
|
|
|
| Bevasiranib sodium |
|
|
|
94.50% |
| Bevasiranib sodium scrambled negative control |
|
|
|
|
| BFH772 |
|
|
|
96.67% |
| BHEPN |
|
|
|
|
| BI-836880 |
|
|
|
|
| BMS-195614 |
|
|
|
99.5% |
| BMS-605541 |
|
|
|
99.57% |
| BMS-645737 |
|
|
|
|
| BMS-690514 |
|
|
|
99.68% |
| BMS-794833 |
|
|
|
99.52% |
| BPTQ |
|
|
|
|
| Bucillamine |
|
|
|
99.04% |
| c-Met-IN-11 |
|
|
|
|
| c-Met-IN-31 |
|
|
|
|
| C-VGB3 |
|
|
|
|
| CA IX/VEGFR-2-IN-2 |
|
|
|
|
| CA IX/VEGFR-2-IN-3 |
|
|
|
|
| Cabozantinib hydrochloride |
|
|
|
|
| Cabozantinib-d4 S-malate |
|
|
|
|
| Capeserod |
|
|
|
98.66% |
| Casdatifan |
|
|
|
96.37% |
| CAY10781 |
|
|
|
98.04% |
| CBO-P11 |
|
|
|
|
| CDK2/FLT4/PDGFRA-IN-1 |
|
|
|
|
| CEP-11981 |
|
|
|
99.88% |
| CEP-11981 tosylate |
|
|
|
|
| CEP-14083 |
|
|
|
|
| CEP-14513 |
|
|
|
|
| CEP-5214 |
|
|
|
|
| CEP-7055 |
|
|
|
|
| Chloramphenicol/BSA |
|
|
|
|
| Chloropyramine hydrochloride |
|
|
|
99.64% |
| cis-SU4312 |
|
|
|
|
| Clausenidin |
|
|
|
|
| CLM3 |
|
|
|
|
| Coibamide A |
|
|
|
|
| COX-2-IN-55 |
|
|
|
99.20% |
| CP-547632 |
|
|
|
99.94% |
| CP-547632 hydrochloride |
|
|
|
99.79% |
| CP-547632 TFA |
|
|
|
98.04% |
| CPD-002 |
|
|
|
|
| Cremastranone |
|
|
|
|
| CS2009 |
|
|
|
|
| cyclo(CLLFVY) |
|
|
|
99.37% |
| CZC-8004 |
|
|
|
99.81% |
| Darlifarnib |
|
|
|
|
| DHW-221 |
|
|
|
|
| DMH4 |
|
|
|
98.20% |
| DOTA-TMVP1446 |
|
|
|
|
| DSPE-PEG1000-Mal-Cys-ATWLPPR |
|
|
|
|
| DSPE-PEG2000-Mal-Cys-ATWLPPR |
|
|
|
|
| DSPE-PEG3400-A7R |
|
|
|
|
| DSPE-PEG5000-A7R |
|
|
|
|
| Dth |
|
|
|
|
| DW10075 |
|
|
|
|
| Efadirelaxin alfa |
|
|
|
|
| Efclarofusp alfa |
|
|
|
|
| Efdamrofusp alfa |
|
|
|
99.89% |
| EG00229 |
|
|
|
|
| EG01449 |
|
|
|
|
| EG01449 Free acid |
|
|
|
|
| EGFR T790M/VEGFR-2-IN-1 |
|
|
|
|
| EGFR-IN-116 |
|
|
|
|
| EGFR-IN-174 |
|
|
|
|
| EGFR-IN-192 |
|
|
|
|
| EGFR-IN-26 |
|
|
|
|
| EGFR-IN-57 |
|
|
|
|
| EGFR-IN-94 |
|
|
|
|
| EGFR/VEGFR2-IN-1 |
|
|
|
|
| EGFR/VEGFR2-IN-10 |
|
|
|
|
| EGFR/VEGFR2-IN-11 |
|
|
|
|
| EGFR/VEGFR2-IN-12 |
|
|
|
|
| EGFR/VEGFR2-IN-13 |
|
|
|
|
| EGFR/VEGFR2-IN-2 |
|
|
|
|
| EGFR/VEGFR2-IN-3 |
|
|
|
|
| EGFR/VEGFR2-IN-4 |
|
|
|
|
| EGFR/VEGFR2-IN-5 |
|
|
|
|
| EGFR/VEGFR2-IN-6 |
|
|
|
|
| EGFR/VEGFR2-IN-7 |
|
|
|
|
| EGFR/VEGFR2-IN-8 |
|
|
|
|
| EGFR/VEGFR2-IN-9 |
|
|
|
|
| Elpamotide |
|
|
|
|
| ENMD-2076 |
|
|
|
99.99% |
| ENMD-2076 Tartrate |
|
|
|
99.66% |
| Enzyme modulator-1 |
|
|
|
|
| EOC317 |
|
|
|
98.01% |
| Erenapurstat |
|
|
|
99.67% |
| EVT801 |
|
|
|
|
| EYE1090 |
|
|
|
|
| EYE1118 |
|
|
|
|
| Famitinib malate |
|
|
|
|
| FGFR1/VEGFR2-IN-1 |
|
|
|
|
| FGFR1/VEGFR2-IN-2 |
|
|
|
|
| FGFR1/VEGFR2-IN-3 |
|
|
|
|
| FGFR3-IN-2 |
|
|
|
|
| FGFRs-IN-1 |
|
|
|
|
| Flt2-11 |
|
|
|
99.71% |
| FLT3-IN-37 |
|
|
|
|
| FLT3/VEGFR2-IN-1 |
|
|
|
|
| Foretinib |
|
|
|
99.45% |
| Foretinib phosphate |
|
|
|
|
| FR 111142 |
|
|
|
|
| Fruquintinib-d6 |
|
|
|
99.47% |
| Fumarranol |
|
|
|
|
| Gandotinib |
|
|
|
99.86% |
| Gersizangitide |
|
|
|
97.16% |
| Girancitug |
|
|
|
98.80% |
| GNQWFI |
|
|
|
99.45% |
| Golvatinib |
|
|
|
99.86% |
| GSK248233A |
|
|
|
|
| GSK2646264 |
|
|
|
99.74% |
| Guluronic acid sodium |
|
|
|
98.0% |
| GW297361 |
|
|
|
98.05% |
| GW549390X |
|
|
|
|
| GW701427A |
|
|
|
|
| GW768505A free base |
|
|
|
99.26% |
| GW806742X |
|
|
|
99.38% |
| GW806742X hydrochloride |
|
|
|
98.30% |
| GW809897X |
|
|
|
|
| hCA/VEGFR-2-IN-1 |
|
|
|
|
| hCA/VEGFR-2-IN-2 |
|
|
|
|
| hCA/VEGFR-2-IN-3 |
|
|
|
|
| hCA/VEGFR-2-IN-4 |
|
|
|
|
| hCA/VEGFR-2-IN-5 |
|
|
|
|
| HDAC-IN-35 |
|
|
|
|
| Henatinib |
|
|
|
|
| Henatinib maleate |
|
|
|
|
| hPV19 |
|
|
|
|
| HSP110-IN-1 |
|
|
|
|
| HSP90-IN-13 |
|
|
|
|
| hVEGF-IN-1 |
|
|
|
99.25% |
| hVEGF-IN-2 |
|
|
|
|
| hVEGF-IN-3 |
|
|
|
99.56% |
| Hydroxytanshinone IIA |
|
|
|
99.83% |
| I194496 |
|
|
|
98.52% |
| Ilorasertib |
|
|
|
99.86% |
| Ilorasertib hydrochloride |
|
|
|
98.48% |
| IMS2186 |
|
|
|
99.96% |
| Inlecitug |
|
|
|
98.62% |
| Isolinderalactone |
|
|
|
98.79% |
| JB-1 |
|
|
|
99.63% |
| JI-101 |
|
|
|
98.99% |
| JI-101 hydrochloride |
|
|
|
|
| JK-P3 |
|
|
|
99.75% |
| JNJ 17029259 |
|
|
|
|
| JNJ-38158471 |
|
|
|
97.02% |
| Jolkinolide A |
|
|
|
98.0% |
| JTE-907 |
|
|
|
98.54% |
| K-106 |
|
|
|
|
| K00546 |
|
|
|
99.48% |
| Ki20227 |
|
|
|
99.51% |
| Ki8751 |
|
|
|
99.76% |
| KLTWQELYQLKYKGI |
|
|
|
99.89% |
| KRN-633 |
|
|
|
99.45% |
| KST012174 hydrochloride |
|
|
|
|
| L-783277 |
|
|
|
|
| Liensinine perchlorate |
|
|
|
99.67% |
| LM-299 |
|
|
|
95.78% |
| Low molecular weight protamine |
|
|
|
98.07% |
| Low molecular weight protamine acetate |
|
|
|
98.64% |
| Lucitanib dihydrochloride |
|
|
|
98.12% |
| LY2457546 |
|
|
|
|
| LY3022856 |
|
|
|
98.84% |
| LYN00101 |
|
|
|
|
| MAZ51 |
|
|
|
99.76% |
| MET kinase-IN-3 |
|
|
|
|
| MG-262 |
|
|
|
95.0% |
| MGCD-265 analog |
|
|
|
98.49% |
| Midostaurin-13C6 |
|
|
|
|
| ML786 |
|
|
|
|
| ML786 dihydrochloride |
|
|
|
|
| MMPP |
|
|
|
98.06% |
| MSB-0254 |
|
|
|
|
| Multi-kinase inhibitor 3 |
|
|
|
|
| Multi-kinase-IN-12 |
|
|
|
|
| Multi-kinase-IN-2 |
|
|
|
|
| Multi-kinase-IN-3 |
|
|
|
|
| Multi-kinase-IN-4 |
|
|
|
|
| Multi-kinase-IN-5 |
|
|
|
|
| Multi-kinase-IN-7 |
|
|
|
|
| Multi-kinase-IN-8 |
|
|
|
|
| Multi-target kinase inhibitor 2 |
|
|
|
99.82% |
| Multi-target kinase-IN-7 |
|
|
|
|
| Multi-target kinase-IN-8 |
|
|
|
|
| MW02 |
|
|
|
|
| Naphazoline-d4 hydrochloride |
|
|
|
|
| Nastorazepide |
|
|
|
99.95% |
| Nastorazepide hemicalcium |
|
|
|
|
| NBM-T-BMX-OS01 |
|
|
|
99.74% |
| Nef-M1 |
|
|
|
|
| NKP608 |
|
|
|
99.88% |
| NODAGA-tris(t-Bu ester) |
|
|
|
96.28% |
| Notoginsenoside R4 |
|
|
|
99.34% |
| NPA101.3 |
|
|
|
|
| NRPa-308 |
|
|
|
98.96% |
| NSC 850745 |
|
|
|
|
| NVP-AAD777 |
|
|
|
|
| NVP-ACC789 |
|
|
|
99.52% |
| NVP-BAW2881 |
|
|
|
98.54% |
| NY0123 |
|
|
|
|
| NYLTHRQ |
|
|
|
|
| Obtustatin |
|
|
|
99.94% |
| ODM-203 |
|
|
|
99.62% |
| Oglufanide disodium |
|
|
|
|
| Orantinib |
|
|
|
98.52% |
| Orobol |
|
|
|
98.14% |
| P8RI |
|
|
|
99.49% |
| Palverafusp alfa |
|
|
|
98.00% |
| Pamufetinib |
|
|
|
98.28% |
| Pamufetinib mesylate |
|
|
|
99.17% |
| PARP/VEGFR3-IN-1 |
|
|
|
|
| Pazopanib-d3 hydrochloride |
|
|
|
|
| PD173074 |
|
|
|
99.86% |
| PDGFRα/β/VEGFR-2-IN-1 |
|
|
|
|
| Pegaptanib sodium |
|
|
|
90.51% |
| Pegaptanib sodium scrambled negative control |
|
|
|
|
| Pentagamavunon-1 |
|
|
|
98.95% |
| Peptide HRH |
|
|
|
|
| Peptide HRH acetate |
|
|
|
97.16% |
| PF 00337210 |
|
|
|
|
| PF 477736 |
|
|
|
99.04% |
| PF-03814735 |
|
|
|
99.45% |
| PI3K/VEGFR2-IN-1 |
|
|
|
|
| Poly-L-lysine hydrobromide (MW 30000-70000) |
|
|
|
|
| Pomalidomide-C5-Dovitinib |
|
|
|
|
| PP121 |
|
|
|
99.51% |
| PP487 |
|
|
|
|
| PROTAC VEGFR-2 degrader-1 |
|
|
|
|
| PROTAC VEGFR-2 degrader-2 |
|
|
|
|
| PROTAC VEGFR-2 degrader-3 |
|
|
|
99.09% |
| PTC299 |
|
|
|
99.71% |
| Pumitamig |
|
|
|
99.6% |
| PX-478 |
|
|
|
99.58% |
| PX-478 free base |
|
|
|
|
| Pz-1 |
|
|
|
99.90% |
| R1530 |
|
|
|
98.29% |
| R916562 |
|
|
|
|
| RAF265 |
|
|
|
99.80% |
| Ranibizumab (anti-VEGF) |
|
|
|
99.60% |
| RC148 |
|
|
|
99.72% |
| Regorafenib mesylate |
|
|
|
|
| rel-Talmapimod hydrochloride |
|
|
|
|
| Rhamnazin |
|
|
|
99.00% |
| RK-20448 |
|
|
|
99.38% |
| RO5323441 |
|
|
|
95.85% |
| S7 |
|
|
|
98.10% |
| SA-PA |
|
|
|
|
| SA-VA |
|
|
|
|
| SAR131675 |
|
|
|
99.85% |
| Scospondistatin |
|
|
|
|
| SCR-1481B1 |
|
|
|
99.95% |
| SCR-1481B1 free base |
|
|
|
99.99% |
| Segetalin A |
|
|
|
99.92% |
| Si5-N14 |
|
|
|
|
| Sitravatinib |
|
|
|
99.57% |
| Sitravatinib malate |
|
|
|
|
| SJ-C1044 |
|
|
|
98.63% |
| SKLB646 |
|
|
|
|
| Sozinibercept |
|
|
|
98.52% |
| SPHINX31 |
|
|
|
99.25% |
| SSGJ-707 |
|
|
|
≥99.0% |
| ST6GAL1-IN-1 |
|
|
|
99.22% |
| SU 5402 |
|
|
|
|
| SU 5402 |
|
|
|
99.78% |
| SU10944 |
|
|
|
|
| SU11606 |
|
|
|
|
| SU11652 |
|
|
|
99.18% |
| SU14813 |
|
|
|
99.11% |
| SU14813 maleate |
|
|
|
99.04% |
| SU1498 |
|
|
|
98.84% |
| SU4312 |
|
|
|
99.74% |
| SU5204 |
|
|
|
99.46% |
| SU5205 |
|
|
|
98.02% |
| SU5208 |
|
|
|
99.48% |
| SU5214 |
|
|
|
98.0% |
| SU5408 |
|
|
|
98.0% |
| Sulfatinib |
|
|
|
99.52% |
| Sunitinib glucuronate |
|
|
|
95.0% |
| Sunitinib Malate |
|
|
|
99.74% |
| Sunitinib-platinum(IV) prodrug-1 |
|
|
|
|
| Sutetinib |
|
|
|
99.27% |
| Sutetinib maleate |
|
|
|
|
| SYHA1813 |
|
|
|
99.46% |
| SYHA1815 |
|
|
|
|
| T-1-MBHEPA |
|
|
|
|
| T-1-MCPAB |
|
|
|
|
| T-1840383 |
|
|
|
|
| Tafetinib |
|
|
|
96.20% |
| Tafetinib analogue 1 |
|
|
|
|
| TAK-593 |
|
|
|
99.66% |
| Takeda-6D |
|
|
|
99.41% |
| Taligantinib |
|
|
|
|
| TAT-N24 |
|
|
|
|
| Tesevatinib |
|
|
|
99.41% |
| Tesevatinib tosylate |
|
|
|
|
| TG 100572 |
|
|
|
|
| TG 100572 Hydrochloride |
|
|
|
98.76% |
| TG 100801 |
|
|
|
98.61% |
| TG 100801 Hydrochloride |
|
|
|
|
| TG 100948 |
|
|
|
|
| TGP-377 |
|
|
|
|
| Theasaponin E1 |
|
|
|
99.08% |
| THR-317 |
|
|
|
|
| TIE-2/VEGFR-2 kinase-IN-1 |
|
|
|
99.91% |
| TIE-2/VEGFR-2 kinase-IN-2 |
|
|
|
99.81% |
| TIE-2/VEGFR-2 kinase-IN-3 |
|
|
|
|
| TIE-2/VEGFR-2 kinase-IN-4 |
|
|
|
|
| TIE-2/VEGFR-2 kinase-IN-5 |
|
|
|
|
| Tinengotinib |
|
|
|
99.57% |
| Tivozanib hydrate |
|
|
|
99.0% |
| Tivozanib hydrochloride hydrate |
|
|
|
99.83% |
| TMVP1446 |
|
|
|
|
| Tosposertib |
|
|
|
99.89% |
| Tovecimig |
|
|
|
97.39% |
| trans-Trimethoxyresveratrol |
|
|
|
99.35% |
| TRK II-IN-1 |
|
|
|
|
| TU-100 |
|
|
|
|
| Tubulin/VEGFR-2-IN-1 |
|
|
|
|
| Tubulin/VEGFR-2-IN-2 |
|
|
|
|
| Tyrphostin A9 |
|
|
|
99.91% |
| Tyrphostin AG1433 |
|
|
|
99.08% |
| UB-925 |
|
|
|
|
| UniPR1331 |
|
|
|
98.57% |
| Valancitug |
|
|
|
97.61% |
| VEGF-IN-1 |
|
|
|
|
| VEGFR-2 ligand-2 |
|
|
|
|
| VEGFR-2-IN-10 |
|
|
|
|
| VEGFR-2-IN-11 |
|
|
|
|
| VEGFR-2-IN-12 |
|
|
|
|
| VEGFR-2-IN-13 |
|
|
|
|
| VEGFR-2-IN-14 |
|
|
|
|
| VEGFR-2-IN-15 |
|
|
|
|
| VEGFR-2-IN-16 |
|
|
|
|
| VEGFR-2-IN-17 |
|
|
|
|
| VEGFR-2-IN-18 |
|
|
|
|
| VEGFR-2-IN-19 |
|
|
|
|
| VEGFR-2-IN-20 |
|
|
|
|
| VEGFR-2-IN-21 |
|
|
|
|
| VEGFR-2-IN-22 |
|
|
|
|
| VEGFR-2-IN-23 |
|
|
|
|
| VEGFR-2-IN-24 |
|
|
|
|
| VEGFR-2-IN-25 |
|
|
|
|
| VEGFR-2-IN-26 |
|
|
|
|
| VEGFR-2-IN-27 |
|
|
|
|
| VEGFR-2-IN-28 |
|
|
|
|
| VEGFR-2-IN-29 |
|
|
|
99.36% |
| VEGFR-2-IN-30 |
|
|
|
|
| VEGFR-2-IN-31 |
|
|
|
|
| VEGFR-2-IN-32 |
|
|
|
|
| VEGFR-2-IN-33 |
|
|
|
|
| VEGFR-2-IN-35 |
|
|
|
|
| VEGFR-2-IN-36 |
|
|
|
|
| VEGFR-2-IN-37 |
|
|
|
99.11% |
| VEGFR-2-IN-38 |
|
|
|
|
| VEGFR-2-IN-40 |
|
|
|
|
| VEGFR-2-IN-41 |
|
|
|
|
| VEGFR-2-IN-42 |
|
|
|
|
| VEGFR-2-IN-43 |
|
|
|
|
| VEGFR-2-IN-44 |
|
|
|
|
| VEGFR-2-IN-45 |
|
|
|
|
| VEGFR-2-IN-46 |
|
|
|
|
| VEGFR-2-IN-47 |
|
|
|
|
| VEGFR-2-IN-5 |
|
|
|
|
| VEGFR-2-IN-5 hydrochloride |
|
|
|
99.51% |
| VEGFR-2-IN-50 |
|
|
|
|
| VEGFR-2-IN-51 |
|
|
|
|
| VEGFR-2-IN-52 |
|
|
|
|
| VEGFR-2-IN-53 |
|
|
|
|
| VEGFR-2-IN-55 |
|
|
|
|
| VEGFR-2-IN-56 |
|
|
|
|
| VEGFR-2-IN-57 |
|
|
|
|
| VEGFR-2-IN-58 |
|
|
|
|
| VEGFR-2-IN-59 |
|
|
|
|
| VEGFR-2-IN-6 |
|
|
|
99.89% |
| VEGFR-2-IN-60 |
|
|
|
|
| VEGFR-2-IN-61 |
|
|
|
|
| VEGFR-2-IN-62 |
|
|
|
|
| VEGFR-2-IN-63 |
|
|
|
|
| VEGFR-2-IN-64 |
|
|
|
|
| VEGFR-2-IN-65 |
|
|
|
|
| VEGFR-2-IN-66 |
|
|
|
|
| VEGFR-2-IN-67 |
|
|
|
|
| VEGFR-2-IN-69 |
|
|
|
|
| VEGFR-2-IN-70 |
|
|
|
|
| VEGFR-2-IN-71 |
|
|
|
|
| VEGFR-2-IN-72 |
|
|
|
|
| VEGFR-2-IN-73 |
|
|
|
|
| VEGFR-2-IN-74 |
|
|
|
|
| VEGFR-2-IN-76 |
|
|
|
|
| VEGFR-2-IN-77 |
|
|
|
|
| VEGFR-2-IN-78 |
|
|
|
|
| VEGFR-2-IN-79 |
|
|
|
|
| VEGFR-2-IN-80 |
|
|
|
|
| VEGFR-2-IN-81 |
|
|
|
|
| VEGFR-2-IN-83 |
|
|
|
|
| VEGFR-2-IN-85 |
|
|
|
|
| VEGFR-2-IN-87 |
|
|
|
|
| VEGFR-2-IN-9 |
|
|
|
|
| VEGFR-2/AKT-IN-1 |
|
|
|
|
| VEGFR-2/AKT-IN-2 |
|
|
|
|
| VEGFR-2/AURKA-IN-1 |
|
|
|
|
| VEGFR-2/BRAF-IN-1 |
|
|
|
|
| VEGFR-2/BRAF-IN-2 |
|
|
|
|
| VEGFR-2/c-Met-IN-1 |
|
|
|
|
| VEGFR-2/c-Met-IN-2 |
|
|
|
|
| VEGFR-2/c-Met/EGFR-IN-1 |
|
|
|
|
| VEGFR-2/DHFR-IN-1 |
|
|
|
|
| VEGFR-2/DHFR-IN-2 |
|
|
|
|
| VEGFR-2/InhA-IN-1 |
|
|
|
|
| VEGFR-2/P-gp-IN-1 |
|
|
|
|
| VEGFR-2/STAT-3-IN-1 |
|
|
|
|
| VEGFR-3-IN-1 |
|
|
|
98.76% |
| VEGFR-IN-1 |
|
|
|
99.07% |
| VEGFR-IN-3 |
|
|
|
|
| VEGFR-IN-5 |
|
|
|
|
| VEGFR-IN-6 |
|
|
|
|
| VEGFR-IN-7 |
|
|
|
|
| VEGFR/PARP-IN-1 |
|
|
|
|
| VEGFR/PD-L1-IN-1 |
|
|
|
|
| VEGFR/PDGFR-IN-1 |
|
|
|
|
| VEGFR2-IN-1 |
|
|
|
|
| VEGFR2-IN-2 |
|
|
|
99.26% |
| VEGFR2-IN-3 |
|
|
|
|
| VEGFR2-IN-4 |
|
|
|
|
| VEGFR2-IN-7 |
|
|
|
99.79% |
| VEGFR2-IN-84 |
|
|
|
|
| VEGFR2-IN-86 |
|
|
|
|
| VEGFR2/HDAC-IN-1 |
|
|
|
|
| VEGFR2/HDAC1-IN-1 |
|
|
|
|
| VGB4 |
|
|
|
|
| VGX-100 |
|
|
|
99.54% |
| VGX200 |
|
|
|
|
| Vorolanib |
|
|
|
99.78% |
| VS 8 |
|
|
|
|
| VT3989 |
|
|
|
99.61% |
| VU 0364439 |
|
|
|
99.42% |
| Vulinacimab |
|
|
|
99.40% |
| VX70 |
|
|
|
|
| WHI-P180 |
|
|
|
99.84% |
| WHI-P180 hydrochloride |
|
|
|
|
| XENP9493 |
|
|
|
|
| XL 999 |
|
|
|
99.01% |
| YF-452 |
|
|
|
|
| YLL545 |
|
|
|
|
| YLT192 |
|
|
|
|
| YM-359445 dihydroxybutanedioate |
|
|
|
|
| YS07 |
|
|
|
|
| Zanzalintinib |
|
|
|
99.91% |
| ZD-4190 |
|
|
|
98.08% |
| ZD-4190 hydrochloride |
|
|
|
|
| Zerumin A |
|
|
|
|
| Zifibancimig |
|
|
|
99.00% |
| Zinc borate |
|
|
|
|
| ZINC09875266 |
|
|
|
|
| Ziv-aflibercept |
|
|
|
95.00% |
| ZK-261991 |
|
|
|
|
| ZM-306416 hydrochloride |
|
|
|
|
| ZM323881 |
|
|
|
|
| ZM323881 hydrochloride |
|
|
|
99.63% |
| Brivanib (alaninate) |
|
|
|
99.45% |
| Tanshinone IIA |
|
|
|
99.78% |
| Lenvatinib-d4 |
|
|
|
99.59% |
| Lenvatinib-d5 |
|
|
|
|
| Lenvatinib-15N,d4 |
|
|
|
98.01% |
| Lenvatinib |
|
|
|
99.75% |
| Lenvatinib N-oxide |
|
|
|
|
| Lenvatinib mesylate |
|
|
|
99.91% |
| Motesanib Diphosphate |
|
|
|
99.86% |
| Sodium Selenite |
|
|
|
99.00% |
| Talmapimod |
|
|
|
98.68% |
| Talmapimod hydrochloride |
|
|
|
|
| Varisacumab |
|
|
|
97.28% |
| Vanucizumab |
|
|
|
95.12% |
| Ivonescimab |
|
|
|
99.13% |
| Rabbit Thrombin |
|
|
|
|
| Vandetanib |
|
|
|
99.85% |
| Vandetanib-d4 |
|
|
|
|
| Vandetanib-d6 |
|
|
|
|
| Vandetanib-13C6 |
|
|
|
|
| Vandetanib trifluoroacetate |
|
|
|
|
| Vandetanib hydrochloride |
|
|
|
|
| Linifanib |
|
|
|
99.39% |
| Linifanib |
|
|
|
|
| Linifanib-d4 |
|
|
|
|
| Monosialoganglioside GM3 (bovine) |
|
|
|
|
| Carebastine |
|
|
|
99.23% |
| Cabozantinib |
|
|
|
99.97% |
| Cabozantinib-d4 |
|
|
|
|
| Cabozantinib-d6 |
|
|
|
98.14% |
| Cabozantinib S-malate |
|
|
|
99.90% |
| Flavokawain C |
|
|
|
99.53% |
| Guluronic acid |
|
|
|
|
| Semaxinib |
|
|
|
99.92% |
| ZM 306416 |
|
|
|
99.80% |
| Caudatin |
|
|
|
99.95% |
| Fursultiamine |
|
|
|
99.71% |
| Fruquintinib |
|
|
|
99.98% |
| OSI-930 |
|
|
|
98.33% |
| Thiabendazole |
|
|
|
99.94% |
| Tubeimoside I |
|
|
|
99.96% |
| Tarcocimab |
|
|
|
98.35% |
| Dovitinib-d8 |
|
|
|
|
| Dovitinib |
|
|
|
99.88% |
| Dovitinib lactate |
|
|
|
99.75% |
| Dovitinib lactate hydrate |
|
|
|
|
| Dovitinib dilactic acid |
|
|
|
|
| Mollugin |
|
|
|
99.79% |
| Olinvacimab |
|
|
|
≥95.0% |
| Oglufanide |
|
|
|
98.93% |
| Ningetinib |
|
|
|
99.63% |
| Ningetinib (Standard) |
|
|
|
|
| Hypothemycin |
|
|
|
98.0% |
| Ningetinib Tosylate |
|
|
|
99.59% |
| Ningetinib Tosylate (Standard) |
|
|
|
|
| Murine Thrombin |
|
|
|
|
| Nintedanib |
|
|
|
99.90% |
| Nintedanib-d3 |
|
|
|
|
| Nintedanib-13C,d3 |
|
|
|
|
| Nintedanib-d8 |
|
|
|
99.90% |
| Nintedanib esylate |
|
|
|
99.96% |
| BIBF 1202 |
|
|
|
99.82% |
| BIBF 1202-13C,d3 |
|
|
|
99.70% |
| BIBF 1202-d3 |
|
|
|
|
| Brolucizumab |
|
|
|
99.90% |
| Brivanib |
|
|
|
99.45% |
| Pazopanib |
|
|
|
99.91% |
| Pazopanib-d6 |
|
|
|
98.0% |
| Pazopanib-13C,d3 |
|
|
|
|
| Pazopanib-d3 |
|
|
|
|
| Ponatinib-d8 |
|
|
|
99.16% |
| Ponatinib |
|
|
|
99.67% |
| Parsatuzumab |
|
|
|
97.40% |
| Conbercept |
|
|
|
98.42% |
| Isomangiferin |
|
|
|
99.60% |
| Lucitanib |
|
|
|
98.94% |
| Toceranib |
|
|
|
97.41% |
| Toceranib-d8 |
|
|
|
99.08% |
| Toceranib phosphate |
|
|
|
99.23% |
| Gamabufotalin |
|
|
|
99.30% |
| Ponatinib hydrochloride |
|
|
|
99.76% |
| Pulocimab |
|
|
|
98.42% |
| Telatinib |
|
|
|
99.37% |
| Tivozanib |
|
|
|
99.80% |
| Tivozanib-d6 |
|
|
|
|
| Quercimeritrin |
|
|
|
99.48% |
| Chloramphenicol |
|
|
|
99.96% |
| Threo-Chloramphenicol-d6 |
|
|
|
|
| Mersalyl |
|
|
|
89.25% |
| Faricimab |
|
|
|
97.97% |
| Famitinib |
|
|
|
98.13% |
| Taurocholic acid-d5 sodium |
|
|
|
|
| Taurocholic acid-d8 sodium |
|
|
|
98.80% |
| Taurocholic acid sodium |
|
|
|
99.82% |
| Taurocholic acid-13C2,15N sodium |
|
|
|
|
| Taurocholic acid-d4 sodium |
|
|
|
|
| Canine Thrombin |
|
|
|
|
| Regorafenib-d3 |
|
|
|
98.0% |
| Regorafenib-13C,d3 |
|
|
|
|
| Regorafenib |
|
|
|
99.93% |
| Regorafenib N-oxide and N-desmethyl (M5) |
|
|
|
|
| Regorafenib N-oxide and N-desmethyl (M5)-d3-1 |
|
|
|
|
| Regorafenib Hydrochloride |
|
|
|
99.09% |
| Regorafenib monohydrate |
|
|
|
99.94% |
| Ripretinib |
|
|
|
98.71% |
| Vatalanib dihydrochloride |
|
|
|
99.68% |
| Vatalanib succinate |
|
|
|
|
| Vatalanib hydrochloride |
|
|
|
|
| Vatalanib |
|
|
|
99.93% |
| Vatalanib-d4 |
|
|
|
|
| Glycine |
|
|
|
99.93% |
| Licoflavone A |
|
|
|
99.95% |
| Telatinib mesylate |
|
|
|
99.74% |
| Medrysone |
|
|
|
99.79% |
| Sorafenib tosylate |
|
|
|
99.98% |
| Sorafenib-d3 tosylate |
|
|
|
|
| Thymoquinone |
|
|
|
99.80% |
| Pazopanib-13C,d3 hydrochloride |
|
|
|
97.51% |
| Pazopanib Hydrochloride |
|
|
|
99.99% |
| Naphazoline hydrochloride |
|
|
|
99.38% |
| Naphazoline nitrate |
|
|
|
99.12% |
| Hypocrellin A |
|
|
|
99.73% |
| Raddeanin A |
|
|
|
98.68% |
| Midostaurin |
|
|
|
99.81% |
| Sotiburafusp alfa |
|
|
|
97.37% |
| Sorafenib-d3 |
|
|
|
98.16% |
| Sorafenib-13C,d3 |
|
|
|
98.35% |
| Sorafenib-d4 |
|
|
|
99.9% |
| Sorafenib |
|
|
|
99.84% |
| Ethyl cinnamate |
|
|
|
99.80% |
| Sunitinib-d10 |
|
|
|
99.89% |
| Sunitinib-d4 |
|
|
|
|
| Sunitinib |
|
|
|
99.04% |
| Icrucumab |
|
|
|
99.9% |
| Suvemcitug |
|
|
|
96% |
| Alizarin |
|
|
|
99.48% |
| Motesanib |
|
|
|
99.96% |
| Liensinine |
|
|
|
99.97% |
| Liensinine Diperchlorate |
|
|
|
99.96% |
| Naphazoline |
|
|
|
99.74% |
| Terrestrosin D |
|
|
|
99.30% |
| Caulerpin |
|
|
|
|
| Cediranib |
|
|
|
99.87% |
| Cediranib maleate |
|
|
|
99.95% |
| Chiauranib |
|
|
|
98.97% |
| Bevacizumab (Anti-VEGFA) |
|
|
|
99.07% |
| Bevacizumab |
|
|
|
98.90% |
| Dilpacimab |
|
|
|
96.88% |
| Jujuboside B |
|
|
|
99.92% |
| Alacizumab |
|
|
|
|
| Axitinib-13C,d3 |
|
|
|
97.80% |
| Axitinib-d3 |
|
|
|
98.07% |
| Axitinib |
|
|
|
99.84% |
| Aflibercept |
|
|
|
96.9% |
| Albendazole |
|
|
|
99.05% |
| Ramucirumab (anti-VEGFR) |
|
|
|
99.9% |